# EDGAR Filing Document

**Accession Number:** 0001822791
**File Stem:** 0001437749-25-022149
**Filing Date:** 2025-7
**Character Count:** 7729
**Document Hash:** 2d052c7d3cfd7ca193ee7cf5fbd9d669
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001437749-25-022149.hdr.sgml**: 20250703

**ACCESSION NUMBER**: 0001437749-25-022149

**CONFORMED SUBMISSION TYPE**: 424B5

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20250703

**DATE AS OF CHANGE**: 20250703

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Clene Inc.
- **CENTRAL INDEX KEY:** 0001822791
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 852828339
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 424B5
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 333-286058
- **FILM NUMBER:** 251106026

**BUSINESS ADDRESS:**
- **STREET 1:** 6550 SOUTH MILLROCK DRIVE, SUITE G50
- **CITY:** SALT LAKE CITY
- **STATE:** UT
- **ZIP:** 84121
- **BUSINESS PHONE:** 801-676-9695

**MAIL ADDRESS:**
- **STREET 1:** 6550 SOUTH MILLROCK DRIVE, SUITE G50
- **CITY:** SALT LAKE CITY
- **STATE:** UT
- **ZIP:** 84121

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Chelsea Worldwide Inc.
- **DATE OF NAME CHANGE:** 20200827

---

| | |
|:---|:---|
|  | **Filed Pursuant to Rule 424(b)(5)** |
| **PROSPECTUS SUPPLEMENT No. 1** | **Registration No. 333-286058** |
| **(To Prospectus dated April 25, 2025 and** |  |
| **Prospectus Supplement dated April 28, 2025)** |  |

---

**Up to $2,015,000**

![clenelogo11percent.jpg](clenelogo11percent.jpg)

**Clene Inc.**

**Common Stock**

This prospectus supplement supplements, modifies and supersedes, only to the extent indicated herein, certain information contained in our prospectus supplement dated April 28, 2025 (the "Prior Prospectus"), which together with the accompanying prospectus dated April 25, 2025, contained in our Registration Statement on Form S-3 (Registration No. 333-286058) (the "Base Prospectus"), relating to the sale of shares of common stock, par value $0.0001 per share, of Clene Inc., from time to time through Canaccord Genuity LLC ("Canaccord") acting as our sales agent pursuant to the terms of the equity distribution agreement dated April 28, 2025 (the "Equity Distribution Agreement") by and between us and Canaccord.

This prospectus supplement should be read in conjunction with, is not complete without, and may not be delivered or utilized except in connection with, the Prior Prospectus and the Base Prospectus, including all supplements thereto and documents incorporated by reference therein. If there is any inconsistency between the information in the Prior Prospectus, Base Prospectus and this prospectus supplement, you should rely on the information in this prospectus supplement. Any information that is modified or superseded in the Prior Prospectus or Base Prospectus shall not be deemed to constitute a part of the Prior Prospectus or Base Prospectus, respectively, except as modified or superseded by this prospectus supplement.

Under the Equity Distribution Agreement we may issue and sell shares of our common stock having an aggregate gross sales price of up to $25,000,000 from time to time through Canaccord acting as sales agent. However, due to the offering limitations applicable to us under General Instruction I.B.6. of Form S-3 and our public float as of the date of this prospectus supplement, and in accordance with the terms of the Equity Distribution Agreement, we are filing this prospectus supplement to supplement and amend, as of July 3, 2025, the maximum aggregate gross sales price of our common stock that may be offered, issued and sold under the Equity Distribution Agreement. Accordingly, we may offer and sell shares of our common stock having a maximum aggregate gross sales price of up to $2,015,000 from time to time through Canaccord, which does not include the shares of our common stock having a maximum aggregate gross sales price of $1,713,263 that were sold pursuant to the Prior Prospectus to date. If our public float increases such that we may sell additional amounts under the Equity Distribution Agreement and the registration statement of which this prospectus supplement and the Prior Prospectus are a part, we will file another prospectus supplement prior to making additional sales.

Sales of our common stock, if any, under this prospectus supplement may be deemed to be an "at the market offering" as defined in Rule 415(a)(4) promulgated under the Securities Act of 1933, as amended (the "Securities Act"). Canaccord is not required to sell any specific number or dollar amount of securities, but will act as our sales agent and use commercially reasonable efforts to sell on our behalf all of the shares of common stock requested to be sold by us, consistent with its normal trading and sales practices, on mutually agreed terms between us and Canaccord. There is no arrangement for funds to be received in any escrow, trust or similar arrangement.

Canaccord will be entitled to a commission of up to 3.0% of the gross sales price per share of common stock sold under the Equity Distribution Agreement. In connection with the sale of our common stock on our behalf, Canaccord will be deemed to be an "underwriter" within the meaning of the Securities Act and the compensation of Canaccord will be deemed to be underwriting commissions or discounts. We have also agreed to provide indemnification and contribution to Canaccord with respect to certain liabilities, including liabilities under the Securities Act or the Securities Exchange Act of 1934, as amended (the "Exchange Act").

You should read this prospectus supplement, the Prior Prospectus, the Base Prospectus, and any additional prospectus supplement or amendment carefully before you invest in our securities.

Our common stock and public warrants are listed on the Nasdaq Capital Market ("Nasdaq") under the symbols "CLNN" and "CLNNW," respectively. On July 2, 2025, the last reported sale price of our common stock and public warrants on Nasdaq was $3.95 and $0.0224, respectively.

As of July 2, 2025, the aggregate market value of our common stock held by our non-affiliates, as calculated pursuant to the rules of the SEC, was approximately $40.5 million, based upon 8,267,206 shares of our outstanding common stock held by non-affiliates at the per share price of $4.90, the closing sale price of our common stock on Nasdaq on June 2, 2025 which is within 60 days of the date of this prospectus supplement. Pursuant to General Instruction I.B.6 of Form S-3, in no event will we sell securities in a public offering with a value exceeding more than one-third of our "public float" (i.e., the market value of our common stock held by our non-affiliates) in any 12-month period so long as our public float remains below $75.0 million. We have sold $11.5 million of securities in reliance on General Instruction I.B.6 of Form S-3 during the 12 calendar months prior to and including the date of this prospectus supplement.

**Investing in our securities involves a high degree of risk. See "*Risk Factors*" section on page S-10 of the Prior Prospectus and other risk factors contained in any applicable prospectus supplement and in the documents incorporated by reference herein and therein.**

We are a "smaller reporting company," as that term is defined under the federal securities laws and, as such, we have elected to comply with certain reduced public company reporting requirements and may elect to do so in future filings.

**Neither the SEC nor any state securities commission has approved or disapproved of these securities or determined if this prospectus supplement is truthful or complete. Any representation to the contrary is a criminal offense.**

**Canaccord Genuity**

**The date of this prospectus supplement is July 3, 2025.**